Three-Dimensional Fluoroscopic Guidance During Transbronchial Cryobiopsy
This study assesses the effectiveness of transbronchial cryobiopsy guided by 3-dimensional fluoroscopy. Transbronchial cryobiopsy is a procedure to collect lung tissue. The main side effect seen after a transbronchial cryobiopsy is pneumothorax (air leaking out of the lung, which may cause a completely or partially collapsed lung). The standard imaging scans used during this procedure are 2-dimensional (like a photo), which can make it difficult for the doctor to know exactly where the biopsy tool is during the procedure. If the exact location of the device is not clear, a patient can be at a higher risk of pneumothorax. Using a 3-dimensional imaging technique may help to decrease the risk of pneumothorax during transbronchial cryobiopsy.
Checked against the public recordLast updated May 15, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- M.D. Anderson Cancer Center
- Interventions being studied
- Other: Electronic Health Record Review; Procedure: Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age 18 years or older * Presence of an intraparenchymal lung lesion for which cryobiopsy is deemed the most appropriate method of biopsy * Ability to provide informed consent Exclusion Criteria: * Acute respiratory failure (defined as oxygen requirement \> 4 L/min by nasal cannula above baseline, or need for any intervention to support ventilation and/or gas exchange for any duration, including invasive and non-invasive positive pressure ventilation, high-flow therapy, non-rebreather mask, or Venturi mask) * Intensive care unit (ICU) admission * Forced vital capacity (FVC) \< 50% or diffusing capacity of the lung for carbon monoxide (CO) (DLCO) \< 35% (if pulmonary function tests are available) * Known or suspected pulmonary hypertension (defined as elevated right ventricular systolic pressure on echocardiogram, if available) * Acute renal failure or chronic kidney disease * Platelets \< 100,000/uL * International normalized ratio (INR) \> 1.5 * Use of anticoagulant therapy that cannot be held for 2 days * Use of antiplatelet therapy (other than baby aspirin) that cannot be held for 5 days * Any bleeding diathesis * Pregnancy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- M D Anderson Cancer CenterHouston, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 15, 2023. Always confirm current availability with the study team.